Nicotine dependence in remission

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Higher NMR was associated with higher nicotine dependence in univariate analysis but this association did not survive multivariate adjustment, consistent with findings among opioid-dependent populatio

Effect: null; r = .18, p = .045 (univariate); not significant in multivariate model

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49

Adding bupropion-SR to nicotine patch and group CBT did not significantly increase 7-day point-prevalence smoking abstinence rates at end of treatment in smokers with unipolar depressive disorders, us

Effect: null; 36% vs 31%, Chi2=0.49